AMAG
$10.01
Amag Pharmaceuticals
$.05
.50%
AMAG
Earnings Whisper ®
N/A
2nd Quarter June 2020
Consensus:  ($0.49)
Revenue:  $57.69 Mil
Thursday
Aug 6
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AMAG reports earnings?
Beat
Meet
Miss

Where is AMAG's stock price going from here?
Up
Flat
Down
Stock chart of AMAG
Analysts
Summary of analysts' recommendations for AMAG
Score
Grade
Pivots
Resistance
$10.64
$10.41
$10.21

$9.98

Support
$9.78
$9.55
$9.35
Tweet
Growth
Description
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the company's key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex?, the company's other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonZoetisBristol-Myers SquibbUltragenyx PharmaceuticalCatalentMerck & Co.